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Abstract  
 
The crystallization of seven active pharmaceutical ingredients (APIs) (acetaminophen (AAP), 
carbamazepine (CBMZ), caffeine (CAF), phenylbutazone (PBZ), risperidone (RIS), 
clozapine base (CPB) and fenofibrate (FF)) was studied in the absence and presence of 
microcrystalline cellulose (MCC) which acted as a heterosurface. Two of the APIs, namely 
AAP and CBMZ, possess hydrogen bond donor (HBD) and hydrogen bond acceptor (HBA) 
functionalities whereas the other five possess HBA functionality only. Density Functional 
Theory (DFT) and Molecular dynamics calculations complemented the experimental study. 
The smallest nucleation rate enhancement was observed for CBMZ at 1.4 times and the 
largest was observed for FF at 16 times. For all the APIs studied, the interfacial energy was 
similar for crystallizations performed in the presence and absence of the heterosurface. By 
contrast, the pre-exponential factor was larger by a factor of ca. 2 and more for 
crystallizations carried out in the presence of the heterosurface. Arising from this study, a 
model of heterogeneous crystallization was developed wherein two influencing factors were 
identified. The first involves the issue of hydrogen bond complementarity between 
heterosurface and API. Hence, a HBD-rich heterosurface will provide a hydrogen-bond 
mediated option for API cluster formation that would otherwise not be specifically available 
in solution to APIs possessing HBAs only. The second factor identified is that the lifetime of 
the hydrogen bond made by an individual API molecule or small API cluster with the 
heterosurface is up to 1,000 times longer than (i) the lifetime of API-API interactions in a 
solution phase, or (ii) the time required for an API molecule to add to a growing crystal. This 
lifetime effect arises from the greater stability of an adsorbed species, and this extended 
lifetime increases the probability that other molecules or small clusters of the API in solution 
will add to the already adsorbed or attached species thus encouraging the heterogeneous route 
to crystallization. 
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1. Introduction 
Crystallization is universal in nature and is of particular significance to the chemical and 
pharmaceutical industry.1 Notably, crystallisation is an attractive isolation step for 
manufacturing as this process not only combines particle formation and purification but also 
controls other properties such as size distribution, morphology and polymorphism, to ensure 
product quality and therefore performance.2-3 Control and scale up of the crystallization 
process remains a challenging task. However, it can be controlled by targeting nucleation, a 
critical step in the process. In recent years, heterogeneous nucleation has emerged as a 
valuable method to not only control nucleation and polymorphism but also to facilitate a 
reduction in induction time.3-9 
Unlike homogeneous nucleation which occurs in an idealised supersaturated liquid, where the 
internal fluctuations of the liquid trigger the crossing of the kinetic barrier to nucleation, 
heterogeneous nucleation occurs in “impure” liquids where surface walls or nucleating agents 
can engender heterogeneity. Heterogeneous nucleation is the process in which molecules in 
solution aggregate on a heterosurface to form crystal nuclei at a solid-liquid interface. This 
assembly of the molecules on the heterosurface occurs through selective and specific 
interactions such as functional group matching10 and lattice matching3; or through non-
specific adsorption of the molecules on the heterosurface11. In the past two decades, materials 
such as self-assembled monolayers,12-14 silanised glass substrates,15-17 pharmaceutical 
excipients,10, 18-20 biocompatible polymers,6-7 synthetic polymers21-26 and porous substrates27 
have been used as heterosurfaces to induce nucleation. Despite a significant amount of 
research work published in this area, the exact mechanism of the heterogeneous nucleation 
process remains unclear. 
The present work focusses on the homogeneous and heterogeneous nucleation of seven active 
pharmaceutical ingredients (APIs) with different molecular functionalities in the absence and 
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presence of a commonly used excipient, microcrystalline cellulose (MCC). The aim is to 
investigate the extent to which hydrogen bonding between the API and the excipient may 
play a role in the mechanism for the heterogeneous nucleation process. It is well-known that 
molecular functionality at the heterosurface / API crystal interface is responsible for 
facilitating nucleation but the exact mechanism is still unclear.22, 28-29 Recently, researchers 
have discussed the influence that API-excipient hydrogen bonding may have on polymorphic 
control during the heterogeneous nucleation process. For example, Lopez-Mejias et al.29 
contended that the heterogeneous nucleation of orthorhombic acetaminophen (AAP) in the 
presence of poly (methyl methacrylate) (PMMA) was a result of the hydrogen bonding 
interaction between PMMA’s carbonyl groups (C=O) and AAP’s phenolic hydroxyl group; 
by contrast, monoclinic AAP nucleated in the presence of poly (n-butyl methacrylate) 
(PBMA) since the latter’s surface is dominated by terminal butyl groups which impart a steric 
effect that alters the orientation of the surface C=O groups, thus hindering hydrogen bond 
formation between PBMA and AAP. Furthermore, Chadwick et al.10 proposed that the ca. 5-
fold reduction in AAP’s induction time upon crystallisation in the presence of D-mannitol 
was due to the favourable functional group matching between AAP and D-mannitol.  
In this light, therefore, this study examined the crystallization of the following seven APIs in 
the presence and absence of MCC with a view to further probing the underlying mechanism 
of heterogeneous nucleation: acetaminophen (AAP), a common analgesic and antipyretic 
drug; carbamazepine (CBMZ), an anticonvulsant drug applied to treat epilepsy and trigeminal 
neuralgia; fenofibrate (FF), an oral medicine used in the treatment of high cholesterol; 
clozapine base (CPB), an atypical antipsychotic agent; risperidone (RIS), an antipsychotic 
medicine mainly used to treat schizophrenia, bipolar disorder, and irritability in people with 
autism; phenylbutazone (PBZ), a nonsteroidal anti-inflammatory drug (NSAID) for the short-
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term treatment of pain and fever in animals, and caffeine (CAF), a central nervous system 
stimulant. 
These seven APIs were selected on the basis of their particular molecular functionalities. As 
such, AAP, CPB and CBMZ each possess hydrogen bond donor (HBD) and hydrogen bond 
acceptor (HBA) groups, whereas RIS, PBZ, CAF and FF possess only HBA groups. MCC 
was selected as the heterosurface based on its widespread use as an excipient in 
pharmaceutical industry, and on its previously reported19 very low solubility in MeOH under 
the prevailing crystallizations conditions of this study. In the context of its molecular 
functionality, MCC possesses both HBA and HBD groups. It was also used because of its 
positive and discriminating behaviour in heterogeneous nucleation19-20 and its processability 
during the later stages of pharmaceutical production.20 
This study is based on the hypotheses that (a) the heterogeneous nucleation parameters for 
API crystallisation in the presence of excipients could be optimised;19 (b) the nucleation rate 
of APIs would be enhanced upon crystallisation in the presence of excipient; and (c) the 
functional group complementarity between API and excipient favours heterogeneous 
nucleation. Heterogeneous nucleation studies reported previously from the group18-20 showed 
that excipients such as MCC, α/β-Lactose and D-mannitol have positive and discriminating 
effects on the heterogeneous nucleation of CBMZ,20 FF18 and AAP.19 Functional group 
complementarity encouraged hydrogen bond formation between API and excipients, and was 
a strong driving force for the nucleation of CBMZ, FF and AAP in the presence of all the 
excipients studied. The optimisation of such process parameters as API supersaturation, API-
excipient contact time, and maximum attainable API loading was successfully achieved, thus 
allowing for good control over the final API crystal size distribution to be exercised. On the 
contrary, these studies have left unanswered questions on (a) how the rate of 
desupersaturation of a range of APIs would vary in the absence and presence of MCC, and 
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(b) the influence of API structures and functionalities on heterogeneous nucleation. The goal 
of this work was to crystallise CBMZ, AAP, CAF, PBZ, RIS, CPB and FF in the absence and 
presence of MCC at different supersaturations to optimise heterogeneous nucleation 
parameters and to use classical nucleation theory to deduce the kinetic parameters of 
nucleation for each API. A second objective was to derive a plausible mechanism for 
heterogeneous nucleation of the APIs in the presence of MCC. By elucidation of the 
mechanism for heterogeneous nucleation for a range of API molecules, appropriate 
crystallisation conditions and heterosurfaces can be selected in silico for individual APIs to 
then generate crystals of desired size and morphology in controlled heterogeneous 
crystallisation processes. 
2. Experimental Section 
2.1. Materials 
Methanol (MeOH, >99.9 %), phenylbutazone (PBZ, >98% pure, CCDC BPYZDO21), and 
acetaminophen (AAP, >98% pure, CCDC HXACAN01) were supplied by Sigma-Aldrich 
and used as-received. Clozapine base (CPB, >98% pure, CCDC NDNHCL01) and 
carbamazepine (CBMZ, >98% pure, CCDC CBMZPN01) were supplied by Novartis and 
used as-received. Caffeine (CAF, >98% pure, CCDC NIWFEE04) was supplied by Alfa 
Aesar and was used as received, while fenofibrate (FF, >98% pure, CCDC TADLIU01) and 
risperidone (RIS, >98% pure, CCDC WASTEP) were supplied by Kemprotec and used as 
received. Microcrystalline cellulose (MCC) (MW:  36000 g/mol) was supplied by FMC 
International and was used as-received. The molecular structures of the excipient, the solvent 
and all seven APIs are presented in Figure 1. 
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Figure 1: The chemical structures of the excipient, the solvent and the seven APIs used in 
this study with the number of hydrogen bond donor (HBD) and hydrogen bond acceptor 
(HBA) groups in each structure shown. 
 
2.2. Determination of the metastable zone widths for selected API-MeOH solutions 
in the absence of excipient 
Previously reported metastable zone width (MSZW) data for CBMZ20, AAP19 and FF18 were 
used to define appropriate processing conditions for their respective crystallizations from 
saturated MeOH solutions in the presence of MCC. As such, saturation temperatures (Tsat), 
crystallization temperatures (Tcry) and cooling rates (°C/min) were defined to ensure that each 
API’s crystallization occurred inside or within 0.5 ̊C of its MSZW. This was done with the 
aim of reducing the likelihood of homogeneous API nucleation (and subsequent crystal 
growth) from the supersaturated MeOH solutions at Tcry and to promote the selective 
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proliferation of API crystal particles via heterogeneous nucleation onto the suspended MCC 
particles.  
MSZWs for the remaining four APIs (CAF, PBZ, CPB and RIS) were determined at a 600 
mL scale in a 1 L LabMax Automated Reactor (Mettler Toledo). Saturated API-MeOH 
solutions, at their respective saturation temperatures, were cooled to 0 ˚C at a cooling rate of 
0.1 ˚C/min for CAF, CPB and RIS, and 0.3 ˚C/min for PBZ while the onset of crystallization 
was monitored in situ via attenuated total reflectance (ATR) - Fourier transform infrared 
(FTIR) spectrometry (iC15 (Mettler Toledo)) in conjunction with iControl software (Mettler 
Toledo). Cooling crystallizations were performed in triplicate and the average temperature for 
the onset of crystallization was used to determine the MSZW 
2.3. Crystallization of API from MeOH in the presence and absence of Excipient 
The crystallization of each API in the absence and presence of excipient from its 
corresponding supersaturated MeOH solution was performed at a 600 mL scale in the 1 L 
LabMax Automated Reactor (Mettler Toledo). Nucleation and %-desupersaturation were 
monitored in situ via ATR-FTIR (iC15 (Mettler Toledo)) in conjunction with iControl 
software (Mettler Toledo). All crystallizations proceeded under isothermal conditions 
following cooling of the respective API-MeOH solution from its saturation temperature (Tsat) 
to a crystallization temperature (Tcry) which generated the desired level of supersaturation (S) 
to effect nucleation; (S = c/c*, where c = the API solubility at Tsat in g API / kg MeOH, and 
c* = the API solubility concentration at Tcry in g API / kg MeOH). Tsat and Tcry used to 
generate the desired S for each API-MeOH solution are presented in Table 1. For those API 
crystallizations performed in the presence of excipient, the amount of excipient added to 
achieve the required maximum attainable API loading (% w/w) at complete desupersaturation 
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of the API-MeOH metastable solutions was calculated as defined in Equation 120. The 
maximum attainable API loading (% w/w) in each case was 25% w/w. 
 		
				(%	/)
=	
(		
	)
(		
	) + (		 	)
	×	100 
(1) 
 
2.4. Solid State characterization of the API-excipient composites 
2.4.1. Powder X-ray Diffraction (PXRD) 
Powder X-ray diffractograms (PXRDs) were recorded on a PANalytical Empyrean 
diffractometer using a Cu radiation source (λ=1.541 Å) at 40 mA and 40 kV. Scans were 
performed between 5 and 35° 2θ at a scan rate of 0.013° 2θ/min. 
2.4.2. Scanning Electron Microscopy 
The habit of the isolated API-excipient composite solid particles was examined by scanning 
electron microscopy (SEM) (JCM-5700 (JEOL)). Samples were gold coated (S150B, 
Edward) and the surface appearances of the isolated API-excipient composite solids were 
compared. 
2.5. Computational Methods 
2.5.1. Density Functional Theory Calculations 
Density Functional Theory (DFT) calculations were applied to investigate the 1:1 API-API 
and API-excipient pair interactions. For this purpose, an API molecule and a dimer of the 
same API were extracted from the crystal lattice of its stable form crystal structure and 
optimized with a B97-D3 Grimme’s functional,30 and a Gaussian-type 6-31G(d,p) basis set.31 
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(Note: for CAF, AAP, and PBZ, the dimers were constructed from the available structural 
information using the Material Studio 7.0 software.) The molecular geometries changed only 
slightly upon gas-phase optimization, preserving the original crystal-like conformation. The 
binding energy of each API dimer was calculated for the lowest energy configuration, after 
probing molecular interactions. Single point energies were calculated using a double hybrid 
B2PLYP-D332 functional combined with an exact Hartree Fock exchange with an MP2-like 
correlation and long-range dispersion corrections with a basis set of quadruple-ζ valence 
quality (def2-QZVPP).33 This methodology has previously been successfully applied for 
small and medium-sized API molecules.34-38 
The binding energy was calculated as follows: 
∆Ebind = EA-B – (EA + EB) 
where, EA-B is the single point energy of the given dimer, while EA and EB are the respective 
single point energies of the isolated monomers, A and B, in the gas phase.  
A similar approach was followed to probe the API-excipient pair interactions. To simplify the 
calculations, the monomer of MCC, glucose, was used to represent the excipient. The 
possible interactions between the hydroxyl groups (-OH) of glucose and the carbonyl group 
(C=O) on APIs were focused on, except for CPB which only contain amine nitrogens as the 
most electronegative centres. 
2.5.2 Molecular Dynamics Simulations 
Molecular dynamics (MD) simulations were employed to quantify the interaction energy of a 
single API molecule in each of the following solid phases: (i) amorphous cellulose, (ii) API 
cluster, and (iii) crystalline API. MD simulations were carried out with two APIs, namely 
AAP and FF. In order to more closely emulate the structure of MCC, an oligomer comprising 
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5 glucose units was constructed. In periodic simulations, a distance of 20 Å between a 
molecule and its mirror images is considered sufficient to prevent self-interactions. In order 
to ensure that the solute molecules are sufficiently separated from their mirror images,  the 
simulation cells constructed were ≥ 45 Å x 45 Å x 45 Å. Simulation cells were constructed 
with the following molecular compositions: (a) 100 molecules of cellulose + 1 molecule of 
FF; (b) 200 molecules of FF (cluster); (c) 288 molecules of FF (crystal, CCDC TADLIU01); 
(d) 100 molecules of cellulose + 1 molecule of AAP; (e) 450 molecules of AAP (cluster); (f): 
560 molecules of AAP (crystal, CCDC HXACAN01). All simulation cells were equilibrated 
within periodic boundary conditions for 350 – 500 ps (solutions) and 100 ps (crystals) at 298 
K and 1 atm, using NPT ensemble, Nose thermostat and Berendsen barostat. Ewald 
summation was used to calculate the electrostatic interactions. At these conditions, uniform 
molecular densities and constant interaction energies were obtained; this gives confidence 
that the simulation times were sufficiently long. 
The interaction energies were calculated according to the procedure described by Zeglinski et 
al.39 with the following modification: the final energies were calculated for the geometry 
optimised structures taken from six time intervals of the final (fully equilibrated) part of the 
MD trajectory. Thus the computed interaction energies represent mean values (n=6 ± SD). 
The simulations were performed using the COMPASS II force field40 along with the force 
field assigned charges as implemented in the Forcite module of the Materials Studio 7.0 
software package. 
2.6. Hydrogen Bond Propensity Calculations 
In order to find the probable HBAs and HBDs for all the APIs, hydrogen bond propensities 
were calculated41 using the program Mercury 3.10.1 as follows. The training dataset for the 
statistical models was composed of molecules extracted from the Cambridge Structural 
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Database (CSD) that contain all of the functional groups present in the target APIs. A logistic 
regression was then applied to the training dataset that allowed the predictions in the form of 
H-bond propensities upon consideration of the environmental variables for the functional 
groups (e.g. aromaticity, steric density) of the target API. The H-bond propensity for a 
donor–acceptor pair can take a value between 0 and 1, where 0 indicates no likelihood of H-
bond formation and 1 indicates that a hydrogen bond will always be found. 
 
3. Results and Discussion 
3.1. Determination of MSZW 
Table 1 summarizes the key processing parameters used during the various crystallizations of 
the seven APIs from their respective saturated MeOH solutions in the presence of the 
excipient heterosurface, MCC. The MSZWs determined during this study for CAF, PBZ,RIS 
and CPB are included in Table 1 along with the previously reported MSZWs for CBMZ20, 
AAP19 and FF18. The MSZWs of CAF (Tsat = 30 ̊C), PBZ (Tsat = 25 ̊C), CPB (Tsat = 40 ̊C) and 
RIS (Tsat = 25 ̊C) were determined to be 5 ̊C (0.1 C̊/min), 9 ̊C (0.3 ̊C/min), 19 ̊C (0.1 ̊C/min) 
and 21 C̊ (0.1 ̊C/min) respectively. Table 1 also summarizes the saturation and crystallisation 
temperatures for all the APIs along with their respective solubilities (in g/g MeOH) at these 
temperatures. Table 1 further indicates that all crystallization temperatures used to generate 
the desired supersaturations reside inside or within 0.5 C̊ of the MSZW based on the data 
presented, thereby favoring heterogeneous nucleation for all the APIs in the presence of MCC 
at the applied supersaturations.   
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Table 1: The applied supersaturations relevant to the Tsat and Tcry temperatures used; the 
solubilities in MeOH at the indicated Tsat and Tcry temperatures; and the MSZW data for the 
seven APIs used in this study. 
API 
Applied 
Supersaturation 
(S) 
Saturation 
temperature 
(T
sat
, ̊C), (Solubility 
at T
sat
 (g/g MeOH)) 
Crystallisation 
temperature 
(T
cry
, ̊C), (Solubility 
at T
cry
 (g/g MeOH)) 
Solubility 
data 
Reference 
MSZW 
(̊C) 
Carbamazepine 
(CBMZ) 
1.15 
25 (0.097) 
20 (0.084) 
42
 9.520 1.23 18 (0.079) 
1.35 15 (0.072) 
Acetaminophen 
(AAP) 
1.12 
25 (0.332) 
20 (0.297) 
43
 19
19 1.25 15 (0.265) 
1.33 12 (0.25) 
Caffeine 
(CAF) 
1.15 
30 (0.0164) 
27.5 (0.0143) 
44
 5this work 1.21 26.5 (0.0135) 
1.32 25 (0.0124) 
Phenylbutazone 
(PBZ) 
1.15 
25 (0.084) 
22.5 (0.073) 
45
 9 this work 1.22 21.5 (0.069) 
1.31 20 (0.064) 
Risperidone 
(RIS) 
1.23 
25 (0.054) 
20 (0.044) 
46
 21 this work 1.35 18 (0.04) 
1.51 15 (0.036) 
Clozapine 
(CPB) 
1.09 
25 (0.0809) 
20 (0.0745) 
47
 19 this work 1.18 15 (0.0686) 
1.28 10 (0.063) 
Fenofibrate 
(FF) 
1.28 
25 (0.077) 
21 (0.06) 
18
 12.5
18 1.37 20 (0.0564) 
1.50 18.5 (0.051) 
 
3.2. Influence of MCC on the induction time of the various APIs from 
supersaturated MeOH solutions  
Figure 2 presents the change in induction times and nucleation rates for the crystallization of 
the seven APIs from supersaturated MeOH solutions in the absence and presence of dispersed 
MCC in terms of variations in API solution concentrations (as measured via in situ FTIR). As 
summarised in Table 2, the induction times for all seven APIs decreased when crystallized in 
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the presence of MCC relative to in its absence. The extent of this decrease varied 
considerably among the APIs despite all crystallizations being designed to generate a 
maximum attainable API loading of 25% w/w on the dispersed excipient heterosurface. As 
such, MCC displays a positive yet discriminating influence over the heterogeneous nucleation 
of the seven APIs. Table 2 also summarises API nucleation rates in the absence and presence 
of MCC (J* and J, respectively, and calculated according to Equation 2 previously reported 
by Mealey et al.34) along with the corresponding nucleation rate ratios (J/J*). When compared 
for the seven APIs, these nucleation rate ratios provide a measure of MCC’s discriminating 
influence over heterogeneous API nucleation. In this regard, MCC’s positive influence is 
most pronounced in the case of FF where its nucleation rate ratio is 16 (S=1.37), least 
pronounced for CBMZ with its ratio of just 1.4 (S=1.35). The nucleation rate ratios of the 
remaining five APIs reside between these two extremes. Being a ‘hydroxyl group rich’ 
hemiacetal, MCC is readily capable of forming hydrogen bonds with APIs possessing HBA 
and HBD groups alike. This capability may facilitate the formation of hydrogen bond 
mediated API clusters on its insoluble heterosurface. In terms of enhancing the likelihood of 
API cluster formation, one might reasonably expect APIs possessing only HBA groups to 
benefit disproportionately more from this facility than those possessing HBA and HBD 
groups, since molecules of the latter already have an inherent ability to hydrogen bond with 
each other en route to cluster formation during nucleation.  
 
#		# ∗	= 	
1
%&'(
	 (2) 
 
where, J or J* is the nucleation rate (nuclei m-3 s-1), tind is the induction time (s), and V is the 
volume of the crystallization solution (m3). 
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Figure 2: %-Desupersaturation for each of the seven API-MeOH solutions in the absence 
(red curve) and presence (blue curve) of MCC at the supersaturations and temperatures 
indicated; volume = 600 mL. 
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3.3. Solid state characterisation of the isolated solids 
With the exception of CPB, the thermodynamically stable form of all the APIs was nucleated 
in the presence of MCC, as confirmed using PXRD and presented in Figure 3. In the specific 
case of CPB, the CPB-MeOH solvate was nucleated in both the absence and presence of 
MCC, as previously reported.47 It is important to note that the applied supersaturations used 
in this work were all calculated with respect to the thermodynamically stable form. Although 
not a primary focus of this work, it is unlikely that sufficiently high supersaturations were 
applied to be supersaturated with respect to metastable polymorphs. 
 
Figure 3: PXRD patterns of (i) the composite solids isolated after complete desupersaturation 
of each of the seven API-MeOH solutions in the presence of MCC at the indicated 
supersaturations and temperatures (red patterns), (ii) MCC (green patterns), and (iii) CPB-
MeOH solvate (calculated) and the other six APIs (blue patterns). 
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Figure 4 presents the SEM micrographs for all the APIs crystallised in the presence of MCC 
along with an SEM micrograph of MCC as a reference. In each case, the irregular shape of 
the API crystal at the API-MCC interface provides evidence to support the heterogeneous 
nucleation and subsequent growth of the API crystals on the surface of the MCC because the 
independent (i.e. homogeneous) crystallisation of an API would typically yield API crystals 
with well-defined edges throughout. Further evidence to support this observed mode of API 
crystal attachment to the MCC surface was obtained using SEM-Raman and was reported 
previously.20 
 
 
Figure 4: SEM micrographs of the composite solids obtained following the crystallization of 
each of the seven APIs from MeOH solutions in the presence of MCC at the indicated 
supersaturations, along with an SEM micrograph of MCC; API crystals are marked with a red 
star. 
 
3.4. Influence of supersaturation on API crystallization in the presence of MCC 
The free energy barrier to nucleation (∆G*c) plays a significant role in determining the 
number and nature of crystals produced, and its magnitude depends on temperature, 
supersaturation and the interfacial energy at the crystal-solution interface (Equation 3). At 
low supersaturations ∆G*c is relatively large, thus critical nuclei are rare. As the 
supersaturation increases, ∆G*c diminishes thus reducing the barrier to the generation of 
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nuclei. Crystals can grow either by following the classical model of exchanging monomers 
with other crystals in a structured way, or via the two-step process where monomers firstly 
combine in an unstructured way, resulting in the formation of poorly structured particles or 
clusters that subsequently crystallise in a second step.48 
 
∆*+
∗ =	
16-./01
234 	
36272	28
 (3) 
where, γ is the interfacial energy, vm is the molecular volume, Na is Avogadro’s constant, k is 
the Boltzmann constant, T is temperature (in Kelvin), and S is the supersaturation. 
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Table 2: The influence of supersaturation on the induction time, the nucleation rate and the 
nucleation rate ratio during the crystallization of each of the seven APIs from MeOH 
solutions in the absence and presence of MCC 
  MCC absent MCC present  
API 
Supersaturation 
(S) 
Induction 
time (min) 
Nucleation rate 
(J
*
, nuclei m
-3
 s
-1
) 
Induction 
time (min) 
Nucleation rate 
(J, nuclei m
-3
 s
-1
) 
Nucleation 
rate ratio 
(J/J
*
) 
Carbamazepine 
(CBMZ) 
1.16 2160 0.01 960 0.03 2.25 
1.22 670 ± 40 0.041 ± 0.002 600 ± 30 0.046 ± 0.002 1.12 ± 0.01 
1.34 110 ± 30 0.25 ± 0.07 80 ± 20 0.35 ± 0.09 1.4 ± 0.01 
Acetaminophen 
(AAP) 
1.12 140 ± 30 0.20 ± 0.04 100 ± 20 0.28 ± 0.06 1.4 ± 0.01 
1.25 100 ± 30 0.28 ± 0.08 60 ± 10 0.46 ± 0.08 1.7 ± 0.01 
1.32 80 ± 10 0.35 ± 0.04 70 ± 8 0.4 ± 0.05 1.14 ± 0.01 
Caffeine 
(CAF) 
1.15 1260 0.02 600 0.05 2.1 
1.21 850 ± 60 0.03 ± 0.002 360 ± 25 0.08 ± 0.006 2.4 ± 0.03 
1.32 700 ± 20 0.04 ± 0.001 240 ± 10 0.12 ± 0.005 2.9 ± 0.04 
Phenylbutazone 
(PBZ) 
1.15 1200 0.02 360 0.07 3.3 
1.21 350 ± 30 0.08 ± 0.007 100 ± 10 0.28 ± 0.03 3.5 ± 0.04 
1.31 60 ± 10 0.46 ± 0.08 30 ± 5 0.92 ± 0.15 2 ± 0.02 
Risperidone 
(RIS) 
1.23 2280 0.01 870 0.03 2.6 
1.34 1370 ± 30 0.02 ± 0.001 370 ± 60 0.08 ± 0.013 4 ± 0.3 
1.51 450 ± 30 0.06 ± 0.004 280 ± 30 0.1 ± 0.011 1.7 ± 0.03 
Clozapine-
MeOH solvate 
(CPB-MeOH) 
1.08 1020 ± 45 0.03 ± 0.001 70 ± 10 0.4 ± 0.057 15 ± 0.43 
1.18 510 ± 30 0.05 ± 0.003 36 ± 5 0.77 ± 0.1 15 ± 0.36 
1.28 256 ± 20 0.11 ± 0.008 12 ± 3 2.31 ± 0.58 21 ± 0.70 
Fenofibrate 
(FF) 
1.28 460 ± 45 0.06 ± 0.006  38 ± 5 0.73 ± 0.01 12 ± 0.16 
1.36 240 ± 20 0.12 ± 0.01 15 ± 3 1.85 ± 0.37 16 ± 0.37  
1.50 33 ± 10 0.84 ± 0.26 8 ± 2 3.47 ± 0.87 4 ± 0.03 
 
Table 2 presents the induction times, the nucleation rates and the nucleation rate ratios (J/J*) 
determined for the crystallization of each of the seven APIs from MeOH solutions in the 
absence and presence of MCC at three different supersaturations. The supersaturations were 
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devised such that crystallisation occurred inside or within 0.5 ̊C of the MSZW, thereby 
reducing the likelihood of homogeneous nucleation in the presence of MCC. The data 
illustrate the extent to which nucleation behaviour can vary among a set of APIs, many 
possessing broadly similar chemical functionalities, i.e. heterocyclic, aromatic, and/or 
carbonyl-rich. For example, the nucleation rate of RIS increased by ca. 4-fold (S = 1.35) in 
the presence of MCC whereas the corresponding increase for FF was far more pronounced at 
ca. 16-fold (S = 1.37). Table 2 also highlights the general, though clearly not absolute, trend 
towards decreasing nucleation rate ratios (J/J*) as S increases. This may be reflective of how 
the driving force for heterogeneous nucleation can be influenced by the particular interplay 
between a given supersaturation and whether a heterosurface is present or not. Indeed, this 
interplay may be further complicated by the potential of the heterosurface to reduce the width 
of the metastable zone. As such, the MSZW is known to be affected by hydrodynamic 
conditions (agitation rate, solution volume, reactor and impeller characteristic dimensions), 
operating conditions (cooling rate, saturation temperature) and other factors such as the 
presence of particulates.49 Hence, to better observe the specific effect of MCC on the 
nucleation of the different APIs, lower supersaturations in the range of 1.25 – 1.35 would 
likely be more apt. 
The nucleation data presented in Table 2 was also used to calculate, the interfacial energy (γ* 
and γ) and the pre-exponential factor (A* and A) in the absence and presence of MCC, 
respectively for each API, Table 3. Kinetic parameters were calculated using the nucleation 
rate equation (Equation 4) published by Kaschiev et al.50 and also used in a previous 
publication from our group.47 
 #(8) = 		8	exp	(−=/	28)	 (4) 
 where,  
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J = Nucleation rate (nuclei m-3 s-1); J(S) implies the nucleation rate at a given 
supersaturation, S 
A = Pre-exponential factor (nuclei m-3 s-1) 
S = Supersaturation 
 = = 	16-0>
2.?@
/ /3(67)/	  
vo = Molecular volume (m
3) (for CBMZ: 3.09 × 10-28 m3, AAP: 2 × 10-28 m3, CAF: 2.21 × 
10-28 m3, PBZ: 4.36 × 10-28 m3, RIS: 4.92 × 10-28 m3, CPB: 4.1 × 10-28 m3 and FF: 5.08 × 
10-28 m3)51 
γef = Interfacial energy of the cluster/solution interface, for heterogeneous nucleation 
(J/m2) 
k = Boltzmann constant (J/K) (1.38 ×10-23 J/K) 
T = Crystallization temperature (K) 
Equation 3 can be re-written as follows: 
 		(# 8)⁄ = 	 − (=/	28)	 (5) 
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Figure 5: A plot of ‘ln(J/S) or ln(J*/S)’ against (1/(T3ln2S)) × 106 that illustrates the 
dependence of nucleation rate on supersaturation for the crystallization of the seven APIs 
from MeOH in the absence (blue diamond) and presence (red square) of MCC at different 
supersaturations; the lines shown are the best linear fits and include the respective line 
equations and R2 values. 
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Best fit linear equations, as presented in Figure 5, were used to calculate the γ* and γ, and A* 
and A for each of the seven crystallization systems in the absence and presence of MCC 
respectively. Previously published literature states that an “interface promotes nucleation by 
lowering interfacial energy of aggregates”29, 52, however the data presented in Table 3 suggest 
that the presence or absence of MCC does not appreciably influence the interfacial energy for 
any of the seven crystallization systems studied here. Yet the interesting finding from this 
study and our previous work47 is that the pre-exponential factor is a major contributing 
parameter to the crystallization process as observed from Table 3. Based on dimensional 
analysis of Equation 4, A must have the same units as J, namely nuclei (or cluster) m-3 s-1. 
Hence we interpret A as the number of clusters of a size less than the critical radius which 
form per cubic metre of supersaturated solution each second. As such, Table 3 indicates that 
the presence of MCC coincides with an increase in the pre-exponential (A*) factor of ca. 2-
fold or more for the crystallization of all the APIs except CBMZ. This signifies that the rate 
of sub-critical size cluster formation is at least 2-fold greater in the presence of MCC for most 
of the APIs, thereby promoting heterogeneous nucleation. 
Table 3: Interfacial energies and pre-exponential factors for the crystallization of the seven 
APIs from MeOH solutions in the absence and presence of MCC, and the related nucleation 
rate ratios. 
API 
Crystallization in the absence of MCC Crystallization in the presence of MCC Nucleation rate 
ratio (J/J
*
), (S) γ* (mJm
-2
) A* (nuclei m
-3
s
-1
) γ (mJm
-2
) A (nuclei m
-3
s
-1
) 
Carbamazepine 
(CBMZ) 
1.51 0.42 1.4 0.41 1.4 (1.35) 
Acetaminophen 
(AAP) 
0.81 0.27 0.92 0.45 1.7 (1.25) 
Caffeine 
(CAF) 
1.02 0.04 1.21 0.11 2.9 (1.32) 
Phenylbutazone 
(PBZ) 
1.1 0.78 1.17 1.53 3.5 (1.22) 
Risperidone 
(RIS) 
0.97 0.05 1.07 0.1 4 (1.35) 
Clozapine-
MeOH solvate 
(CPB-MeOH) 
0.54 0.08 0.58 1.42 15 (1.18) 
Fenofibrate 
(FF) 
1.54 1.82 1.29 5.66 16 (1.37) 
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3.5. Analysis of Intermolecular Interactions 
Many APIs possess hydrogen bond donors (HBDs) and hydrogen bond acceptors (HBAs) 
which facilitate the formation of strong or weak intermolecular or intramolecular hydrogen 
bond interactions.53 It is well known in the literature that strong and specific hydrogen bond 
interactions can play a significant role in crystallisation kinetics54 and the thermodynamic 
stability of solids.41 In this context, the logit hydrogen-bonding propensity (LHP) model is a 
method used to predict which donors and acceptors form hydrogen bonds in a crystal 
structure, based on the statistical analysis of hydrogen bonds in the Cambridge Structural 
Database (CSD).41 The model defines hydrogen bond propensity, π, as a probability measure 
for the formation of an intermolecular hydrogen bond between specified donor and acceptor 
atoms on two adjacent molecules within a crystal structure, with an assumption that the 
hydrogen bond interaction responsible for the formation of a given crystal will be between 
the strongest possible donor-acceptor pairs.41 The extent of intermolecular hydrogen bond 
interactions is influenced by the following factors: (a) the presence of HBDs and HBAs 
groups on the molecules, (b) the degree of steric hindrance related to the HBDs and HBAs, 
and (c) the chemical and electronic influence of these HBDs and HBAs.55 The π values 
between API-API molecules relevant to this work are presented in Table 4. Therefore, based 
on the logit LHP model, CBMZ and AAP are capable of bonding inter-molecularly with 
molecules of their own kind, since they both possess HBDs and HBAs. Hence CBMZ and 
AAP exhibit hydrogen bond propensities of 0.79 and 0.59 respectively, as shown in Table 4. 
By contrast, CAF, PBZ, RIS and FF all lack HBDs and only contain HBAs; they are 
therefore not capable of hydrogen bonding with molecules of their own kind, hence their 
hydrogen bond propensity values of zero in Table 4 for them. CPB forms CPB-MeOH 
solvate upon crystallisation from methanol in the absence and presence of MCC. In CPB-
MeOH crystal structure, methanol blocks the only HBD site of CPB, leaving HBAs to 
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hydrogen bond with MCC, as reported in the work published previously from the group.47 
This changes the π value to zero for the CPB-MeOH solvate from a value of 0.22 for CPB 
base. 
Comparing the hydrogen bond propensity of each API with its nucleation rate ratio shows 
that APIs with large values of π, presented lower nucleation rate ratios whereas the APIs with 
π value of zero exhibited higher nucleation rate ratios. This signifies that MCC has a weaker 
influence on the nucleation rate of APIs capable of forming a hydrogen bond with 
themselves, such as CBMZ and AAP. All APIs can hydrogen bond with MCC, thereby 
providing support to immobilise molecules of these APIs on the MCC surface and hence 
increase the nucleation rate ratios. As discussed before, MCC has several hydrogen bond 
donors, hydroxyl groups (-OH), on its surface which can hydrogen bond with the HBA polar 
atoms of APIs, i.e. nitrogen and oxygen. This acceptor-donor interaction between MCC and 
APIs increases the nucleation rate of APIs in the presence of MCC in order of FF followed by 
CPB-MeOH solvate, RIS, PBZ, CAF, AAP and CBMZ. This also explains the small change 
in A* for CBMZ (Table 3) because of its high hydrogen bond propensity to another molecule 
of CBMZ, thereby favouring homogeneous and heterogeneous nucleation concomitantly, as 
reported previously.20  
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Table 4: Correlation of number of hydrogen bond donor and acceptor group of each API 
with their hydrogen bond propensity, binding energy between API-API and API-Glucose, 
and nucleation rate ratio 
API 
Number 
of HBDs 
Number 
of HBAs 
Binding energy (kJ/mol) Hydrogen bond 
propensity, π 
Nucleation rate 
ratio (J/J
*
), (S) API-API API-Glucose 
Carbamazepine 
(CBMZ) 
1 3 -33.8 -17.6 0.79 1.4 (1.35) 
Acetaminophen 
(AAP) 
2 2 -60.0 -20.9 0.59 1.7 (1.25) 
Caffeine 
(CAF) 
0 6 -24.7 -23.4 0 2.9 (1.32) 
Phenylbutazone 
(PBZ) 
0 4 -18 -22.8 0 3.5 (1.22) 
Risperidone 
(RIS) 
0 6 -12 -34 0 4 (1.35) 
Clozapine-MeOH 
solvate 
(CPB-MeOH) 
0 4 -11.9* -22.5* 0 15 (1.18) 
Fenofibrate 
(FF) 
0 3 -7.9 -34.6 0 16 (1.37) 
*CPB-MCC binding energy was calculated instead of CPB-MeOH solvate and MCC, to avoid the complexity of 
methanol in the system 
3.6. Interaction energies from DFT calculations  
Table 4 also presents the binding energies of the various API-API dimers and API-glucose 
dimers. These data support the argument that hydrogen bonding between the HBDs of MCC 
and the HBAs of the APIs is the driving force for heterogeneous nucleation of the APIs 
during their crystallization in the presence of MCC. Though the HBAs of each API can form 
hydrogen bonds with the HBDs of glucose, the extent of these interactions will likely vary 
depending on each API’s specific molecular structure. As such, the API-API interaction is 
stronger in the cases of AAP and CBMZ than the corresponding API-glucose interaction, an 
observation that correlates with the rather modest increase in their respective nucleation rate 
ratios. By contrast, the binding energies of the FF-FF dimer and the FF-glucose dimer are 
considerably different, at -7.9 kJ/mol and -34.6 kJ/mol respectively. Indeed the API-API 
binding energies are less than the API-glucose binding energy for all the APIs possessing 
only HBA’s. This correlates to the significant increase in the nucleation rate ratio for those 
particular APIs. Also, the calculated differences in binding energies between the various API-
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API and API-glucose dimer pairs are consistent with the related API hydrogen bond 
propensities, and both these parameters in turn are good indicators of the trend in nucleation 
rate ratios. In essence, APIs with only HBAs will only hydrogen bond with the HBDs of the 
heterosurface, but this interaction ultimately facilitates the sequestering of an API cluster on 
the heterosurface thus increasing the nucleation rate ratio of the API. Figure 6 presents the 
optimized geometry of the API-API and API-Glucose dimers for each of the seven APIs 
along with the respective binding energies in kJ mol-1. Each of the API-glucose structures in 
Figure 6 features H-bonding interactions.  (Note: CPB-MCC binding energy was calculated 
instead of CPB-MeOH solvate and MCC, to avoid the complexity of methanol in the system)  
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.  
Figure 6: Optimized geometries of the various API-API and API-Glucose dimers (B97-
D3/6-31G(d,p) level). Binding energy in kJ mol-1, calculated at B2PLYP-D3/def2-QZVPP 
level; Hydrogen – white, carbon – grey, oxygen – red, nitrogen – blue, fluorine – pale green, 
chlorine – green. 
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3.7. Interaction energies from Molecular Dynamics Simulations 
The DFT calculations presented in Table 4 offer a useful insight into the specific 
intermolecular interactions between the molecules in dimers. However, using the simple 1:1 
models, it is not possible to fully capture and quantify the whole interaction space around an 
API molecule. To overcome this limitation, molecular dynamics simulation was employed; a 
simulation cell filled with hundreds of molecules was used. Here an oligomer comprising five 
glucose units was also used in order to more closely approximate the bulk structure of MCC. 
MD simulations were considered for two APIs, one had induction times influenced only 
slightly (AAP) and one significantly (FF) by the presence of the MCC additive. A 
comparison of the interaction of a single molecule of each API in three different scenarios 
(namely embedded in bulk cellulose, as part of an amorphous API cluster, and as part of the 
API crystalline phase) is shown in Figure 7. 
 
Figure 7: Graphical representations and interaction energies for a single molecule of AAP 
and FF embedded within: a matrix of cellulose, (a) and (d); an amorphous API cluster, (b) 
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and (e); an API crystalline structure, (c) and (f). The API molecule in (a) and (d) is 
highlighted in yellow. 
For AAP, the weakest interaction was observed for the single API molecule interacting with 
cellulose (-216.3 kJ mol-1), followed by a significantly stronger interaction when in the 
amorphous cluster phase (-252.1 kJ mol-1), while the strongest (i.e. most stable) interaction 
was for the AAP molecule in its crystalline phase (-276.8 kJ mol-1). In the case of FF, the 
interaction strength was the highest (i.e. most stable) for the FF molecule interacting with 
bulk cellulose (-330.9 kJ mol-1), followed closely by the interaction energy in the FF crystal 
(-327.7 kJ mol-1), while the interaction strength in its amorphous cluster phase was 
significantly lower (-292.5 kJ mol-1). 
When comparing the two different systems, it appears that an AAP molecule is energetically 
stabilised by 36 kJ mol-1 in the amorphous phase relative to its interaction with cellulose. 
Further stabilisation takes place when this amorphous cluster transforms to a crystalline 
phase. In contrast, FF’s most preferential state is its interaction with cellulose, which is 
comparable with the API-API interaction within FF crystals. The lowest interaction energy 
(i.e. the least stable interaction) is recorded for the FF molecule embedded in its amorphous 
phase.  
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Discussion 
The lifetimes of hydrogen bond interactions play an important role in governing the 
heterogeneous nucleation process.18, 47 Table 5 collates typical literature values for the 
average lifetimes of single molecules attached to a surface by hydrogen bonds and the time 
required to form critical sized nuclei (at ca. 25 C̊) attached to solid surfaces via hydrogen-
bonding. These lifetimes vary in the range from < 10 ns to < 70 ns for the first interaction of 
single molecules and 1-200 ns for critical nuclei depending on the desorption energy of the 
hydrogen bond involved.56-59  In general, the lifetime of a specific hydrogen bond interaction 
in solution is typically 100 -1000 time less at 0.001 to 0.07 ns.60-61 Table 6 presents the time 
required (tm) to add a single molecule to growing crystals of the seven APIs investigated in 
this work. These values were calculated from the growth phases of Figure 2 for each of the 
APIs using Equation 6;62 tm values were calculated in the range 0.001-0.3 ns molecule
-1.  
 
1 =	
B	C
DEFG	(H	3E
	 (6) 
 
where, tg is time required for a single crystal to grow to a certain size (s) (obtained from the 
growth phase of APIs in Figure 2), Mw is the molecular mass of the API (g/mol), ρAPI is 
density of the API (g/m3) (for APP: 1.26 × 106 g/m3, CBMZ: 1.30 × 106 g/m3, PBZ: 1.20 × 
106 g/m3, CAF: 1.23 × 106 g/m3, CPB: 1.3 × 106 g/m3, RIS: 1.4 × 106 g/m3, FF: 1.18 × 106 
g/m3),51 Vp is the volume of the API particle (m
3) calculated using the particle diameter from 
SEM micrographs (particle diameter for AAP: 20µm, CBMZ: 20µm, PBZ: 100µm, CAF: 
50µm, CPB-MeOH solvate: 100µm, RIS: 70µm and FF: 76µm), and NA is Avogadro’s 
constant (6.023 × 1023 mol-1). 
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Table 5: Literature values for the interaction lifetimes for various heterogeneous 
nucleating systems. 
System 
First interaction 
lifetime (ns) 
Critical nuclei/crystal 
formation lifetime (ns) 
Reference 
CO2 hydrate on SiO2 < 70 1 – 160 
57 
Ice nucleation on AgI 
surface  
< 11 36 56 
Ice nucleation on 
Graphite 
< 10 15  58 
Secondary nucleation 
on Bicalutamide 
surface 
< 15 15 – 200 59 
 
In general, large values of tm were calculated when the particle size was small or when the 
growth time was long. The lifetime of a single API molecule attached to a solid surface by 
hydrogen bonding as well as the average lifetime for nucleus formation (Table 5) is several 
orders of magnitude longer than the time required to add a single molecule to a growing API 
crystal (Table 6). Alternatively, the adsorbed API can exist attached to a surface for a time 
scale which will allow the attachment of multiple API molecules from the solution phase and 
facilitate the formation of nuclei and eventually stable crystals. In the solution phase API-API 
interactions are much shorter-lived increasing the difficulty of nucleus formation.  
Table 6: Time required for each API to add one molecule to an API cluster/crystal 
API 
Time required to add one 
molecule, tm (ns molecule
-1
) 
Carbamazepine  
(CBMZ) 
0.3 
Acetaminophen  
(AAP) 
0.23 
Caffeine  
(CAF) 
0.046 
Phenylbutazone  
(PBZ) 
0.002 
Risperidone  
(RIS) 
0.052 
Clozapine-MeOH solvate  
(CPB-MeOH) 
0.001 
Fenofibrate 
 (FF) 
0.003 
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The lifetime effect also helps to explain the modest enhancement in nucleation rates for 
CBMZ and AAP. All of our previous studies with AAP and CBMZ indicate that mature 
crystals of these APIs still attach to the MCC surface apparently favouring the heterogeneous 
route to crystallization. Here we argue that those AAP or CBMZ molecules which adhere to 
MCC stay on the surface for longer times than the duration of the corresponding API-API 
solution phase interactions.  This increases the probability that other AAP or CBMZ 
molecules will attach as individual molecules or as small clusters to the MCC-bound 
molecules, thus facilitating the eventual development of mature crystals attached to the MCC 
surface. Hence, the heterogeneous nucleation observed for AAP and CBMZ is due to the 
“lifetime effect” whereby the MCC attached AAP or CBMZ molecule exists for long enough 
to allow other AAP or CBMZ molecules or small clusters to attached via API-API 
interactions.   
For FF and other APIs without HBD functionality the lifetime effect operates in conjunction 
with the complementarity of functional groups to give much stronger accelerations of the 
crystallization of these molecules in the presence of MCC.  
Our experimental and modelling results allow us to propose a mechanism for the 
heterogeneous nucleation of APIs in the presence of the MCC. A schematic representation of 
the two distinct modes of the API aggregation in solution in the presence MCC is shown in 
Figure 8 for AAP which possesses HBD and HBA functionality and for FF which possesses 
only HBA functionality.   
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Figure 8:  Schematic representation of two distinct modes of progression of solute 
aggregation in the presence of MCC: left (A-C) – formation of H-bond clusters of 
acetaminophen (AAP) in solution and on MCC surface; right (D-E) – adsorption and 
stabilisation of the fenofibrate (FF) cluster at polar surface of MCC. H-bonds between MCC 
and API molecules shown as dotted lines.  
Hence for AAP, we can envisage AAP-AAP interactions in the solution phase which would 
result in a relatively quick formation of small molecular aggregates of solute molecules, 
which, being reinforced by H-bonds may be sufficiently stable to further grow into crystal 
nuclei in the absence of a heterosurface. The introduction of a polar heterosurface (provided 
by MCC) promotes a modest reduction in AAP’s induction time relative to the reductions 
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observed for the other APIs studied. The AAP crystals which form all seem to be associated 
with the MCC surface despite the binding energies for AAP-Glucose and CBMZ-Glucose 
both being less than the AAP-AAP and CBMZ-CBMZ binding energies.  This effect is 
explained here in terms of the lifetime effect discussed above. Essentially, the mechanism 
outlined in Figure 8 envisages the formation of small clusters of AAP in a solution in contact 
with MCC. These may attach as small clusters or as individual molecules to the MCC. The 
longer lifetimes of these attached structures over the corresponding structures in solution 
favour the heterogeneous crystallization route. 
APIs possessing only HBAs, such as FF, are incapable of forming H-bond mediated 
aggregates/clusters of solute molecules.  Thus aggregates rely instead on Van der Waals 
interaction to mediate cluster formation in solution, and that these interactions are much 
weaker than H-bond interactions. This results in relatively longer nucleation times in the 
absence of the heterosurface. It appears from the experimental results that by introducing the 
polar MCC heterosurface, the nucleation process of such APIs becomes significantly 
shortened. Both the DFT and MD modelling results show consistently that the polar hydroxyl 
groups present on MCC are efficient H-bond donors towards API molecules possessing only 
HBAs, such as FF. Thus the polar heterosurface facilitates efficient 
immobilisation/stabilisation of the FF molecules at the MCC particles. It could be envisaged 
that initially individual molecules or small clusters of FF would be adsorbed, followed by 
formation of surface adsorbed semi-structured aggregates of API, which upon reaching 
sufficient stability and size, could subsequently convert into crystalline phases. In effect, 
APIs without HBD functionality are encouraged to nucleate in the presence of MCC by virtue 
of the complementary HBD capacity of MCC and through the “lifetime effect” whereby 
individual API molecules can exist on the MCC surface for 10-1000 folds longer than the 
time required to add a single molecule to a developing nucleus.  
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Conclusions   
The heterogeneous nucleation of seven APIs, namely CBMZ, AAP, CAF, PBZ, RIS, CPB 
and FF, was performed from methanol solutions in the presence of MCC. MCC displayed a 
positive yet discriminating influence over each API’s heterogeneous nucleation in terms of 
the enhancement in API nucleation rate it conferred. As such, though all seven APIs 
nucleated at a faster rate in the presence of MCC than in its absence, those APIs possessing 
both HBD and HBA groups (and therefore able to hydrogen bond with other molecules of 
themselves) experienced a smaller enhancement in their nucleation rate in the presence of 
MCC relative to the APIs possessing HBA groups only. Despite the observed increases in 
nucleation rates, the thermodynamically stable form of each API was nucleated in the 
presence of MCC, as confirmed using PXRD and SEM; in the specific case of CPB, the 
thermodynamically stable form is the methanol solvate. DFT and molecular dynamics 
simulations were consistent with the experimental results, whereby APIs possessing only 
HBA groups readily formed hydrogen bonds with the HBD groups of MCC; and this 
interaction facilitated the sequestering of the API molecules on to the MCC surface, thus 
promoting heterogeneous nucleation of the API. The experimental data support the view that 
MCC’s presence did not influence the heterogeneous nucleation by lowering the interfacial 
energy required for nucleation but instead by increasing the pre-exponential factor (A*) by 2-
fold and more.  In conclusion, when crystallized in the presence of HBD-rich heterosurfaces, 
APIs possessing only HBA functionality will exhibit a more pronounced reduction in 
induction times than APIs possessing HBAs and HBDs. This phenomenon will also be 
influenced by the lifetime of the interactions between the API and the heterosurface whereby 
adsorbed APIs are characterised by a much longer lifetime than the lifetime of API-API 
interactions in solution or the time required to add new API molecules to a growing API 
crystal. 
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Influence of hydrogen bonding complementarity and lifetime in heterogeneous nucleation of 
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